Tag Archives: WaveSense

February 2017—WaveSense introduced its nRichDX system for the bulk isolation of target cells and nucleic acids from liquid biopsies. The nRichDX uses the company’s proprietary paramagnetic bead technology to enable the capture of circulating tumor cells and cell-free DNA or cell-free RNA in quantities sufficient for analysis by next-generation sequencing and PCR techniques.

May 2015—WaveSense, a manufacturer of in vitro diagnostic cell targeting, enrichment, and isolation products for pathology, urology, and oncology, added a product to its line of cell enrichment applications delivered through its patented EpiSep medical product line.